← Back to guidelines
Nutrition38 papers

Biotin-thiamine-responsive basal ganglia disease

Last edited: 4/14/2026

Overview

Biotin-thiamine-responsive basal ganglia disease (BT1-RD) is an inherited metabolic disorder characterized by neurological symptoms that improve with biotin and thiamine supplementation 1.

Diagnosis

  • Elevated plasma 3-hydroxyisovaleryl carnitine (3HIA-carnitine) concentration can serve as a biomarker for biotin deficiency 3.
  • Clinical presentation includes neurological symptoms such as encephalopathy, hypotonia, and movement disorders 1.
  • Genetic testing to identify specific mutations associated with the condition may be warranted 1.
  • Management

  • First-line Treatment: High-dose biotin supplementation is essential 1.
  • Adjunctive Treatment: Thiamine supplementation is recommended alongside biotin to manage symptoms effectively 1.
  • Monitoring of biotin status through biomarkers like plasma 3HIA-carnitine may guide treatment adjustments 3.
  • Special Populations

  • Pediatrics: Careful administration of biotin is crucial in infants and children due to unique metabolic needs and potential for deficiency 1.
  • Pregnancy: Specific guidelines for biotin supplementation during pregnancy are not detailed in the provided abstracts, but biotin deficiency can impact embryonic development 2.
  • Key Recommendations

  • Initiate high-dose biotin supplementation in patients diagnosed with biotin-responsive disorders to manage neurological symptoms effectively (Evidence: Expert opinion 1).
  • Consider plasma 3HIA-carnitine levels as a biomarker to monitor biotin status and guide supplementation adjustments (Evidence: Moderate 3).
  • Provide thiamine alongside biotin supplementation to optimize clinical outcomes in BT1-RD (Evidence: Expert opinion 1).
  • References

    1 Wolf B. Revisiting the administration of biotin to children with biotin-responsive disorders. Molecular genetics and metabolism 2022. link 2 Quick M, Shi L. The sodium/multivitamin transporter: a multipotent system with therapeutic implications. Vitamins and hormones 2015. link 3 Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J, Mock DM. Quantitative measurement of plasma 3-hydroxyisovaleryl carnitine by LC-MS/MS as a novel biomarker of biotin status in humans. Analytical chemistry 2010. link 4 Said HM. Cell and molecular aspects of human intestinal biotin absorption. The Journal of nutrition 2009. link

    Original source

    1. [1]
    2. [2]
    3. [3]
      Quantitative measurement of plasma 3-hydroxyisovaleryl carnitine by LC-MS/MS as a novel biomarker of biotin status in humans.Horvath TD, Stratton SL, Bogusiewicz A, Pack L, Moran J, Mock DM Analytical chemistry (2010)
    4. [4]
      Cell and molecular aspects of human intestinal biotin absorption.Said HM The Journal of nutrition (2009)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG